Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-01-24
DOI
10.3389/fonc.2019.01519
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
- (2019) Alice Guazzelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
- (2019) Neil Bayman et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
- (2019) Emilie M. J. van Brummelen et al. INVESTIGATIONAL NEW DRUGS
- Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study
- (2019) Dean A. Fennell et al. JOURNAL OF CLINICAL ONCOLOGY
- The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo.
- (2019) Uri Weinberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
- (2019) Prasad S. Adusumilli et al. JOURNAL OF CLINICAL ONCOLOGY
- Return to Intended Oncologic Treatment After Surgery for Malignant Pleural Mesothelioma
- (2019) David B. Nelson et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
- (2019) Raffit Hassan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
- (2019) Michele Carbone et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma
- (2019) Raffit Hassan et al. CLINICAL CANCER RESEARCH
- Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)
- (2019) Morihito Okada et al. CLINICAL CANCER RESEARCH
- A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
- (2019) Robert A. Belderbos et al. Translational Lung Cancer Research
- Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
- (2019) Anne S. Tsao et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial
- (2019) Isabelle Opitz et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2019) S Popat et al. ANNALS OF ONCOLOGY
- 1226PA phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
- (2019) A Curioni et al. ANNALS OF ONCOLOGY
- NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma
- (2018) Tatsuhiro Sato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Hedy L. Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
- (2018) Dean A. Fennell et al. Trials
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
- (2018) Luana Calabrò et al. Lancet Respiratory Medicine
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma
- (2018) Neelam Kumar et al. LUNG CANCER
- Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
- (2018) Linda Ye et al. Expert Review of Respiratory Medicine
- Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
- (2017) Arnaud Scherpereel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
- (2017) Emma Beddowes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
- (2017) Federica Grosso et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
- (2017) Anne S. Tsao et al. Journal of Thoracic Oncology
- OA20.06 Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project
- (2017) Boris Sepesi et al. Journal of Thoracic Oncology
- OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
- (2017) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
- (2017) H.L. Kindler et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
- (2017) Nico van Zandwijk et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group
- (2017) Scott A. Laurie et al. LUNG CANCER
- BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
- (2017) Angela Bononi et al. NATURE
- CAR T-cell therapy for lung cancer and malignant pleural mesothelioma
- (2017) Masha Zeltsman et al. Translational Research
- Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis
- (2017) Zi-Yi Zhao et al. Oncotarget
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
- (2017) Rachel M. Gibbons Johnson et al. Frontiers in Immunology
- Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma
- (2017) Simone B. S. P. Terra et al. OncoImmunology
- Oncolytic Viral Therapy for Mesothelioma
- (2017) Daniel F. Pease et al. Frontiers in Oncology
- Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
- (2016) Robin Cornelissen et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2016) J. C. Soria et al. ANNALS OF ONCOLOGY
- CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
- (2016) M. Betti et al. CANCER LETTERS
- Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
- (2016) Jingli Zhang et al. CLINICAL CANCER RESEARCH
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil
- (2016) Takashi Nakano et al. Expert Review of Anticancer Therapy
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
- (2016) Chrisann Kyi et al. Immunotherapy
- Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
- (2016) Andreas Rimner et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016
- (2016) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
- (2016) Marc de Perrot et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes
- (2016) Wieneke A. Buikhuisen et al. Journal of Thoracic Oncology
- Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles
- (2016) Pascal Andujar et al. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
- (2016) Amelia O Clive et al. LANCET ONCOLOGY
- Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
- (2016) Matthew Locke et al. Cell Reports
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) P. Baas et al. ANNALS OF ONCOLOGY
- Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors
- (2015) Emilio Minatel et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Successful Combined Intratumoral Immunotherapy of Established Murine Mesotheliomas Requires B-Cell Involvement
- (2015) Shruti Krishnan et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2
- (2015) Hyun Joo Chung et al. Oncotarget
- Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma
- (2014) David J. Sugarbaker et al. ANNALS OF SURGERY
- Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
- (2014) R. Hassan et al. CLINICAL CANCER RESEARCH
- A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
- (2014) B.C. John Cho et al. Journal of Thoracic Oncology
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- (2014) Aaron Scott Mansfield et al. Journal of Thoracic Oncology
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
- (2013) G. Reid et al. ANNALS OF ONCOLOGY
- Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
- (2013) S Jane Henley et al. INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH
- Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
- (2013) Sophie Papa et al. Journal of Thoracic Oncology
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
- (2013) H. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma
- (2012) Kenneth E. Rosenzweig et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
- (2012) Anna K. Nowak et al. Journal of Thoracic Oncology
- Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
- (2012) Loïc Lang-Lazdunski et al. Journal of Thoracic Oncology
- Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium
- (2012) Nicholas P. Campbell et al. LUNG CANCER
- A Trial of Intrapleural Adenoviral-mediated Interferon-α2b Gene Transfer for Malignant Pleural Mesothelioma
- (2011) Daniel H. Sterman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
- (2011) M. H. Abdel-Rahman et al. JOURNAL OF MEDICAL GENETICS
- Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
- (2011) Scott A. Laurie et al. Journal of Thoracic Oncology
- Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma
- (2011) Loïc Lang-Lazdunski et al. Journal of Thoracic Oncology
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
- (2011) Linda L. Garland et al. Journal of Thoracic Oncology
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
- (2011) Tom Treasure et al. LANCET ONCOLOGY
- Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
- (2011) Thierry Jahan et al. LUNG CANCER
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- An In Vivo Platform for Tumor Biomarker Assessment
- (2011) Elliot L. Servais et al. PLoS One
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
- (2010) Y. Zhao et al. CANCER RESEARCH
- Trimodality Treatment of Malignant Pleural Mesothelioma
- (2010) Hasan Fevzi Batirel et al. Journal of Thoracic Oncology
- A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
- (2010) Sarita Dubey et al. Journal of Thoracic Oncology
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
- (2009) A. Scherpereel et al. EUROPEAN RESPIRATORY JOURNAL
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma
- (2009) Lee M. Krug et al. JOURNAL OF CLINICAL ONCOLOGY
- miRiad Roles for the miR-17-92 Cluster in Development and Disease
- (2008) Joshua T. Mendell CELL
- Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
- (2008) Masaki Anraku et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started